Follow Us
https://www.thebody.com/category/hiv-drugs-development/tag/news

The Latest

Screenshot from Carl Dieffenbach and Anne Rancourt Final IAS 2019 Video

Updates on HIV Treatment Advances and Other Notes From IAS 2019

NIAID's Carl Dieffenbach, Ph.D., joins Anne Rancourt to discuss some key takeaways from the 10th International AIDS Society Conference on HIV Science.

PrEP Trials: The Benefits -- and Challenges -- of Seeking Community Input Img

PrEP Trials: The Benefits -- and Challenges -- of Seeking Community Input

Last fall, community activists voiced concerns over the roll out of studies on Descovy (TAF/FTC) as pre-exposure prophylaxis (PrEP) without adequately involving community advisors.

Joseph Eron, Jr., M.D., presents 96-week study data from LATTE-2, at IAS 2017 (Credit: Warren Tong)

Long-Acting Injectable HIV Treatment Moves Closer to Reality

Long-acting injectable treatment takes another step closer to being a real-world option for people living with HIV, with new study results presented at IAS 2017.

Surprise FDA Approval of Generic Truvada Is a 'Wakeup Call' for Activists Img

Surprise FDA Approval of Generic Truvada Is a 'Wakeup Call' for Activists

The surprise approval of generic Truvada (tenofovir disoproxil fumarate and emtricitabine) by the U.S. Food and Drug Administration (FDA) on June 9 left patients, advocates and doctors scrambling to understand exactly when the generic will become ava...

Real or Not? HIV Cure in Animals Using CRISPR Gene Editing Img

Real or Not? HIV Cure in Animals Using CRISPR Gene Editing

You may have heard about the "HIV cure with gene editing in animals" story. Here's some help making sense of the story, including what's true or not, and what to get excited about.

People With Multidrug-Resistant HIV Can Now Start Treatment on the Experimental Drug Ibalizumab Img

People With Multidrug-Resistant HIV Can Now Start Treatment on the Experimental Drug Ibalizumab

For the small percentage of HIV patients struggling with drug resistance, an expanded access program for a new injectable treatment might be the answer.

protesters

Why Are HIV Groups Charging Gilead With Bad Behavior in New PrEP Trial?

"Gilead is not following the accepted standard for community engagement in its new pre-exposure prophylaxis (PrEP) trial," write Anna Forbes and Marc-André LeBlanc, explaining that concern is inspired, in part, by controversies in earlier PrEP trials...

cure

All Stakeholders Must Be Engaged in HIV Cure Research, Webinar Says

Participating in an HIV cure trial is not an isolated event, but must be seen in the "landscape of engagement" -- the range of other issues the participant may be facing, such as discrimination or a lack of stable housing. Stakeholder participation i...

Congress Challenges FDA Blood Donor Deferral Policy Img

Congress Challenges FDA Blood Donor Deferral Policy

Members of the U.S. House and Senate have signed on to "Dear Colleague" letters to the FDA Commissioner asking him to lift the one-year blood donor deferral policy on men who have sex with men.

With HIV Cure as the Goal, Gene Therapy Research Expands Img

With HIV Cure as the Goal, Gene Therapy Research Expands

What if someone could have HIV in his or her body, but the virus was incapable of causing harm? That's the tantalizing promise of a "functional cure" for HIV. A new trial will evaluate if gene therapy can achieve this goal.